VEGFA and renal cell adenocarcinoma: The identification of dysregulated signaling pathways in vascular endothelial growth factor (VEGF) and the mammalian target of rapamycin (mTOR) in the progression of RCC has led to the development and approval of molecules targeting these pathways for therapeutic purposes [9].